Sarat Sethi says that Zoetis Inc. (NYSE: ZTS), is an excellent choice for anyone looking to gain exposure in the pet category. Sethi is a managing director at DCLA.
Sethi bought Elanco and loaded up on Zoetis in the past week. He said, “My theme over the last couple of weeks has been to upgrade the stock quality.”
The category of pets is his choice, as it has been deemed to be resistant to recessions.
Sethi says that Zoetis’ stock has lost almost 15% in value over the last three months.
What makes Zoetis superior to Elanco stock?
Sethi believes that Zoetis is a leader in the animal health care industry, despite a challenging macroeconomic climate this year.
He added that the firm based in Parsippany, NJ, is not subject to regulatory problems, which are common with big-pharma companies.
Investors are advised to note that ZTS has grown at a faster rate than Elanco.
The world’s leading producer of pet medicine and vaccines reported an annualised revenue growth rate of 5.0% in its Q4 fiscal.
Elanco’s revenue, on a reported-basis, declined by 1.0% in the fourth quarterly.
ZTS has a better balance sheet.
The market expert recently told CNBC that Elanco Animal Health Inc. is a great stock to hold in 2025.
He prefers Zoetis to ELAN because ELAN’s debt is four times larger than its equity.
Sethi pointed out that ZTS offers both a strong balance sheet and global presence, which make it a good stock to buy ahead of any potential recession.
He likes Zoetis better than Elanco because the latter currently pays 1.33%. ELAN does not pay dividends at the time of writing.
Wall Street is with Sethi about Zoetis Inc
Zoetis’ financial results in February exceeded Street expectations. Kristin Peck, Zoetis’ chief executive, told investors at the time:
We’re excited to keep the momentum going as we near 2025. Our success is based on sustainable drivers, which will allow us to continue above market growth in this year’s and future years.
Zoetis expects a revenue growth of up to 8,0% in 2025.
Wall Street shares DCLA’s Sarat sethi’s view on Zoetis.
ZTS’s shares are currently rated “overweight”. The mean price target is $204, which indicates a potential rise of 35% over current prices.
The post Elanco stock vs Zoetis: Sarat sethi chooses one side could be updated as new information becomes available
This site is for entertainment only. Click here to read more
